title: The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study.
abstract: In hypoparathyroidism, plasma parathyroid hormone (PTH) levels are inadequate to maintain plasma calcium concentration within the reference range. On conventional treatment with calcium supplements and active vitamin D analogues, bone turnover is abnormally low, and BMD is markedly increased. We aimed to study the effects of PTH-replacement therapy (PTH-RT) on calcium-phosphate homeostasis and BMD. In a double-blind design, we randomized 62 patients with hypoparathyroidism to daily treatment with PTH(1-84) 100 µg or similar placebo for 24 weeks as add-on therapy to conventional treatment. Compared with placebo, patients on PTH(1-84) reduced their daily dose of calcium and active vitamin D significantly by 75% and 73%, respectively, without developing hypocalcemia. However, hypercalcemia occurred frequently during the downtitration of calcium and active vitamin D. Plasma phosphate and renal calcium and phosphate excretion did not change. Compared with placebo, PTH(1-84) treatment significantly increased plasma levels of bone-specific alkaline phosphatase (+226% ± 36%), osteocalcin (+807% ± 186%), N-terminal propeptide of procollagen 1 (P1NP; +1315% ± 330%), cross-linked C-telopeptide of type 1 collagen (CTX; +1209% ± 459%), and urinary cross-linked N-telopeptide of type 1 collagen (NTX; (+830% ± 165%), whereas BMD decreased at the hip (-1.59% ± 0.57%), lumbar spine (-1.76% ± 1.03%), and whole body (-1.26% ± 0.49%) but not at the forearm. In conclusion, the need for calcium and active vitamin D is reduced significantly during PTH-RT, whereas plasma calcium and phosphate levels are maintained within the physiologic range. In contrast to the effect of PTH(1-84) treatment in patients with osteoporosis, PTH-RT in hypoparathyroidism causes a decrease in BMD. This is most likely due to the marked increased bone turnover. Accordingly, PTH-RT counteracts the state of overmineralized bone and, during long-term treatment, may cause a more physiologic bone metabolism.
authors.affiliation: Department of Metabolism and Internal Medicine, MEA, THG, Aarhus University Hospital, Aarhus, Denmark. Tanja.sikjaer@gmail.com
authors.forename: Tanja
authors.initials: T
authors.lastname: Sikjaer
authors.forename: Lars
authors.initials: L
authors.lastname: Rejnmark
authors.forename: Lars
authors.initials: L
authors.lastname: Rolighed
authors.forename: Lene
authors.initials: L
authors.lastname: Heickendorff
authors.forename: Leif
authors.initials: L
authors.lastname: Mosekilde
mesh_terms: D000328:Adult; D000368:Aged; D001205:Ascorbic Acid / Q000008:administration & dosage; D015519:Bone Density; D002118:Calcium / Q000008:administration & dosage / Q000378:metabolism; D005260:Female; D006706:Homeostasis; D006801:Humans; D007011:Hypoparathyroidism / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000009:adverse effects / Q000627:therapeutic use*; D010758:Phosphorus / Q000378:metabolism; D010919:Placebos
chemical_list: D010281:Parathyroid Hormone; D010919:Placebos; D010758:Phosphorus; D001205:Ascorbic Acid; D002118:Calcium